Heather Arranie 
Medical cannabis includes the products derived from cannabis which are used in the treatment or management of health issues under medical supervision. The main working ingredients, tetrahydrocannabinol (THC) and cannabidiol (CBD), affect the body through the endocannabinoid system which modulates myriad functions like pain, mood, appetite and sleep, among others.
While THC has psychoactive effects, CBD does not get one intoxicated, but instead garners interest for its potential in treating various conditions including anxiety, depression, and even epilepsy.
Since the implementation of medical cannabis policy in the UK in 2018, interest towards its applications has been growing. Only a specialist doctor has the authority to grant prescriptions, and these are usually made when other means of treatment have been tried without success. Unfortunately, access through NHS remains limited, with only very few prescriptions being offered through public healthcare systems. This has resulted in a rise in the use of private medical services for those wanting to access cannabis-based therapies.
While cannabis is still an illicit drug, its use in medicine is subject to regulation and strict clinical supervision. Its prescriptions are based on existing clinical evidence of its safety and appropriateness. Thus, there is adequate differentiation between the medical and recreational use of cannabis, and there are robust triage systems ensuring compliance with the legal and medical usage of cannabis.
Applications Across a Spectrum of Health Conditions
Medical cannabis is now being accessed in the UK and other countries to mitigate a variety of conditions such as chronic pain, neurological disorders, gastrointestinal complaints, mental health issues, and certain types of treatment-resistant epilepsy. The recent surge in the number of patients seeking treatment at private medical cannabis clinic suggests that there is an increase in clinical cannabis awareness and legal access of its availability.
Clinic data in 2023 indicated a 10-fold increase in patient registrations over a single-year span. The most common cases were psychiatric disorders like anxiety and post-traumatic stress symptoms, followed by patients needing assistance with chronic pain and advanced-stage pain management. Significantly, almost 40% of the participants attending reported chronic pain as the main ailment of concern. This shows some change in patient attitude in terms of switching to available pain-relief alternatives when conventional medicine routes do not help them achieve the desired relief.
The process of applying for a private cannabis prescription requires the patient to undergo several medical examinations. They have to fulfill specific eligibility guidelines like having some medical documentation and prior use of first-line treatments like treatment protocols of the first-line therapy. This belief driven skepticism surrounding prescription approaches guarantee that it’s medically justified and not based on personal preference of the patient’s choosing.
Medical cannabis clinics work under this regulatory framework. They provide consultation with specialist prescribers who evaluate patients and help with ongoing treatment management. These clinics are usually privately financed and provide patients with a wide variety of clinically-grade cannabis products. Treatment is customized and constantly revised according to the needs and requirements of the patient while focusing on safety and symptom suppression.
Although the public’s comprehension of medical cannabis has undoubtedly improved in recent times, there still exists some ambiguity regarding its therapeutic purposes and unregulated recreational use. Medical professionals still put great emphasis on clinical supervision, careful diagnosing, and protecting the patient as pivotal elements of care.
Integrating Cannabis into Holistic Health Approaches
The implementation of medical cannabis into more holistic approaches to health management is currently being looked at in many fields. Besides pain and psychiatric disorders, it is being studied for inflammatory conditions, some women’s health concerns like endometriosis, and in supporting cancer symptoms of nausea and appetite loss.
One research direction that is emerging is the consideration of the economic value of medical cannabis when prescribed within a controlled healthcare system. Modelling has shown that treating chronic pain patients who are already within the NHS with cannabis-based therapies would be economically beneficial by lowering the utilization of other NHS services.
These estimates are based on the expectation of reduced GP consultations, reduced hospital admissions, and reduced prescribing of other more potent medications like opioids or antidepressants, which are often more easily abused or have more severe side effects.
Professional education and training still lack adequate attention, even as interest increases. Almost all healthcare professionals report having an insufficient knowledge of cannabinoid medicine, which could undermine their confidence in discussing possible treatment modalities with patients. The need for formal instruction and updated clinical guidelines may be necessary for wider adoption into practice.
A patient’s knowledge contributes to their willingness to use the treatment. In a survey done in the UK in 2023, over half the adults claimed to be suffering from a condition that could warrant consideration for treatment using cannabis. Surprisingly, only a small fraction sought or received a legal prescription. This presents opportunities and challenges: the possibility of providing a safe and legal means to a large population of patients who could benefit and highlighting the need to ensure awareness is matched by clinically appropriate access.
Central to this process are the quality and safety of medical cannabis products. The illicit-use cannabis marketed by self-treating chronic conditions is known to contain contaminants including mould, heavy metals, and bacteria. In contrast, medical-grade products are manufactured and tested to stringent standards, greatly reducing the risks associated with unregulated use.
In clinical practice, medical cannabis is becoming one more component in an integrated treatment care plan. It is seldom employed as a first approach and is most frequently applied when other alternatives have been attempted or have resulted in severe side effects. In this case, cannabis therapies may complement physiotherapy, counselling, nutrition, exercise, or even basic medications.
As more cannabis-infused medicinal products are developed and regulatory frameworks advance, it would be intuitive to think that more sophisticated approaches will arise concerning medical cannabis and its management. Systematic and ongoing clinical evaluations of real-life evidence will ultimately determine the strategy, treatment, and technological regulations policymakers set in the forthcoming years.
